middle.news
How Prescient’s PTX-100 Fast Track Could Transform CTCL Treatment
9:51am on Wednesday 30th of July, 2025 AEST
•
Healthcare
Read Story
How Prescient’s PTX-100 Fast Track Could Transform CTCL Treatment
9:51am on Wednesday 30th of July, 2025 AEST
Key Points
FDA grants Fast Track designation for PTX-100 in relapsed/refractory CTCL
First patient dosed in Phase 2a clinical trial across Australia, US, and Europe
Melanie Farris appointed as independent Non-Executive Director
Cash balance stands at AUD 6.9 million with spending aligned to budget
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE